Drug Hunter has filed a notice of an exempt offering of securities to raise $7,043,380.00 in New Funding.
According to filings with the U.S. Securities and Exchange Commission, Drug Hunter is raising up to $7,043,380.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.
About Drug Hunter
Drug Hunter is a B2B media and information services company dedicated to empowering innovators in drug discovery by providing a comprehensive platform for learning and career growth. The company’s mission is to distill critical insights from across the industry, including journals, patents, and conference abstracts, into an easy-to-use platform for busy scientists. This platform offers curated scientific content, real-time analysis of publications and patents, and an integrated search interface to help pharmaceutical R&D teams accelerate discovery and solve complex challenges. Founded in 2018, Drug Hunter aims to be the go-to resource for drug discovery innovators, offering products and subscription services like drughunter.com, a newsletter, events, and a premium subscription to make drug discovery science more accessible.
To learn more about Drug Hunter, visit https://drughunter.com/
Drug Hunter Linkedin Page: https://www.linkedin.com/search/results/companies/?keywords=Drug%20Hunter
Contact:
Dennis Hu, Chief Executive Officer
650-458-7087
SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.
